Christopher Ryan
About Christopher Ryan
Christopher Ryan serves as the Chief Operating Officer at Synedgen, Inc, a position he has held since 2019. He has extensive experience in pharmaceutical manufacturing and research, having worked in various roles at Synedgen and UCLA over the past two decades.
Current Role at Synedgen
Christopher Ryan serves as the Chief Operating Officer at Synedgen, Inc, a position he has held since 2019. In this role, he oversees the company's operational strategies and ensures efficient management of resources. His leadership contributes to the advancement of Synedgen's mission in the pharmaceutical industry.
Previous Experience at Synedgen
Prior to his current role, Christopher Ryan held several positions at Synedgen, Inc. He was the Vice President of Manufacturing from 2018 to 2019, the Director of Pharmaceutical Manufacturing from 2013 to 2018, and the Associate Director of Pharmaceutical Development from 2012 to 2013. His tenure at Synedgen has been marked by significant contributions to manufacturing and development processes.
Education and Academic Background
Christopher Ryan earned a Bachelor of Science degree in Biochemistry from the University of Rochester, where he studied from 1995 to 1999. He later obtained a PhD in Microbiology with a focus on Molecular Parasitology from the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo, completing his studies from 1999 to 2005.
Research Experience at UCLA
Ryan worked at UCLA in various capacities, including as a Postdoctoral Fellow from 2005 to 2010 and as a Staff Research Associate from 2010 to 2012. His research during this period contributed to advancements in his field and provided a foundation for his later work in the pharmaceutical industry.
Key Contributions to Medical Device Development
Christopher Ryan has been involved in significant projects, including the development and implementation of a program to formulate, test, and clear a 510(k) medical device aimed at treating oral wounds. He also led technology transfers for two wound care medical devices to a new contract manufacturing organization and managed the expansion of a proprietary molecule library.